According to DBX's own information in the public domain, the study is powered for GFR slope on a sample size of 286. It is highly unlikely that looking at GFR slope in 50% of patients will have sufficient power to get the necessary positive result.
Ann: Dimerix presentation at Bioshares Biotech Summit, page-26
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
-0.005(1.06%) |
Mkt cap ! $255.8M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 48.5¢ | 46.5¢ | $1.514M | 3.204M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 121059 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.5¢ | 106197 | 4 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |